Press Releases

SHANGHAI, China, April 2, 2024 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it was a winner of the 2024 CDMO Leadership Awards in all six categories – Capabilities, Compatibility, Expertise, Quality, Reliability, and Service – across all three groups of Big Pharma, Small Pharma and Overall. In addition, the company was named a “Champion” for its particularly high ratings in the categories of Compatibility and Service for the Small Pharma group.

This is the seventh consecutive year the CDMO Leadership Awards have recognized WuXi Biologics. The company has established collaborations with global clients, providing them with expertise, leading technologies and biologics research, development and manufacturing services to quickly and cost-effectively advance biologics and vaccines from concept to commercial manufacturing.

In the past year alone, WuXi Biologics has facilitated 110 IND fillings. To date, the company has passed over 1,200 client quality audits, completed 33 regulatory inspections conducted by the U.S. FDA, EU EMA, China NMPA and other global regulatory agencies, and maintained PPQ success of 97%+ for drug substance and drug product manufacturing, demonstrating a proven track record of premier quality.

Dr. Chris Chen, CEO of WuXi Biologics, commented, “We are honored to have been recognized by pharma companies across all the CDMO Leadership Awards benchmark categories. This is a testament to the extraordinary performance of our highly dedicated staff worldwide and the trustworthiness we have earned enabling our clients to efficiently advance their breakthrough treatments to market and ultimately benefit patients. “

The CDMO Leadership Awards are presented by Outsourced Pharma and Life Science Leader. For the 2024 awards, 72 contract manufacturing organizations – identified based on authoritative third-party research – were evaluated on more than 23 different performance metrics by pharma and biopharma companies who have utilized these outsourcing services within the past 18 months.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Business

info@wuxibiologics.com

Media

PR@wuxibiologics.com